ScienceAstraZeneca’s COPD drug wins two late-stage trials, boosting blockbuster hopes
AstraZeneca’s COPD drug delivered positive results in two late-stage trials. The full data strengthens hopes that it could become a breakthrough treatment and achieve peak annual sales of more than $5 billion.
C
CNBC★★☆☆☆2026-09-08 11:45Original
AstraZeneca’s COPD drug wins two late-stage trials, boosting blockbuster hopes
Science